Class / Patent application number | Description | Number of patent applications / Date published |
514651000 | Ether oxygen is part of the chain | 56 |
20080200555 | USE OF NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF TIC DISORDERS - Selective norepinephrine reuptake inhibitors are used to treat tic disorders. | 08-21-2008 |
20080269346 | B-Blocker Pharmacogenetics in Heart Failure - Polymorphisms in the beta-1 adrenergic receptor that (1) affect tolerability to beta-blocker treatment or (2) influence responsiveness to beta-blocker treatment are disclosed. Additionally, methods of predicting that an individual would obtain clinical improvement in left ventricular function as a result of β-blocker therapy or identifying at least one individual that would obtain a clinical improvement in left ventricular function as a result of β-blocker therapy are provided. Methods of treating patients characterized by such polymorphisms are also illustrated. | 10-30-2008 |
20080319086 | DEUTERIUM-ENRICHED SALMETEROL - The present application describes deuterium-enriched salmeterol, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 12-25-2008 |
20090030084 | Compositions and Methods of Use of Electron Transport System Inhibitors - The invention provides compounds of the formula: or a pharmaceutically acceptable salt thereof, where m, n, R | 01-29-2009 |
20090069440 | DEUTERIUM-ENRICHED ATOMOXETINE - The present application describes deuterium-enriched atomoxetine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-12-2009 |
20090099265 | TRANS-CLOMIPHENE FOR METABOLIC SYNDROME - The present invention relates to the administration of compositions comprising an antiestrogen, preferably trans-clomiphene, for treating metabolic syndrome in a subject. The invention is also directed to methods for reducing fasting glucose levels in a subject by administering a composition comprising an antiestrogen, preferably trans-clomiphene. | 04-16-2009 |
20090105349 | ANDROGEN MODULATORS - The present invention is directed to the discovery of a new class of androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease sebum secretion and to stimulate hair growth. | 04-23-2009 |
20090215906 | METHODS AND MATERIALS WITH TRANS-CLOMIPHENE FOR THE TREATMENT OF MALE INFERTILITY - Compositions comprising trans-clomiphene for treating male infertility may be used to treat male infertility. | 08-27-2009 |
20090215907 | DOSING REGIMES FOR TRANS-CLOMIPHENE - The present invention relates to the use of compositions comprising trans-clomiphene for treating men with hypogonadism. The invention is also directed to methods for treating males with hypogonadism and disorders related thereto, including reduction of muscle mass, limitation of body performance capacity, reduction of bone density, reduction of libido, reduction of potency, reduction of benign prostatic hyperplasia and infertility. | 08-27-2009 |
20090281195 | NOVEL COCRYSTALLIZATION - The present disclosure relates to novel cocrystals and novel methods for cocrystallization. In particular, the disclosure includes cocrystals comprising a salt of an active agent, such as a chloride salt of an active pharmaceutical ingredient. The present disclosure also relates to methods of preparing cocrystals and methods for screening for solid state phases. | 11-12-2009 |
20090286883 | TREATMENT OF HEART FAILURE AND ASSOCIATED CONDITIONS BY ADMINISTRATION OF MONOAMINE OXIDASE INHIBITORS - Administration of monoamine oxidase inhibitors is useful in the prevention and treatment of heart failure and incipient heart failure. | 11-19-2009 |
20100081720 | DEUTERIUM-ENRICHED ATOMOXETINE - The present application describes deuterium-enriched atomoxetine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 04-01-2010 |
20100113606 | AMINOPROPANOL MODULATORS OF BETA-1 ADRENERGIC RECEPTOR - The present invention relates to new aminopropanol modulators of beta-1 adrenergic receptor activity, pharmaceutical compositions thereof, and methods of use thereof. | 05-06-2010 |
20100240763 | Method to Determine and Biomarker for Treatment Efficacy With Ssri, Snri, and Sari Antidepressants - The invention provides a method for determining whether a patient suffering from a condition that is susceptible to treatment with a compound that activates the brain serotonin system is resistant to treatment with the compound. The method comprises observing whether the genome of the patient contains at least one copy of the BDNF allele containing a genetic alteration, and correlating the presence of the allele containing the genetic alteration with patients who are resistant to treatment with the compound. In another embodiment, the method comprises observing whether the patient expresses a BDNF protein containing an amino acid alteration, and correlating the expression of the BDNF protein containing the amino acid alteration with patients who are resistant to treatment with the compound. | 09-23-2010 |
20100286281 | METHODS AND MATERIALS FOR THE TREATMENT OF TESTOSTERONE DEFICIENCY IN MEN - The present invention relates to the use of compositions comprising trans-clomiphene for treating men with hypogonadism. The invention is also directed to methods for treating males with hypogonadism. | 11-11-2010 |
20110021635 | RBM3 AS A MARKER FOR BREAST CANCER PROGNOSIS - The present invention provides means, such as a method, for determining whether a prognosis for a mammalian subject having a breast cancer is better than a reference prognosis. The method comprises the steps of: providing a sample earlier obtained from the subject; evaluating the amount of RBM3 protein present in at least part of said sample, and determining a sample value corresponding to said evaluated amount; comparing the sample value obtained with a reference value associated with said reference prognosis; and, if said sample value is higher than said reference value, concluding that the prognosis for said subject is better than said reference prognosis. | 01-27-2011 |
20110118358 | DEUTERIUM-ENRICHED SALMETEROL - The present application describes deuterium-enriched salmeterol, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 05-19-2011 |
20110136914 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY - Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described. | 06-09-2011 |
20110207827 | METHOD FOR DETERMINING SENSITIVITY OR RESISTANCE TO COMPOUNDS THAT ACTIVATE THE BRAIN SEROTONIN SYSTEM - The invention relates to a method for determining whether a patient suffering from a condition that is susceptible to treatment with a compound that activates the brain serotonin system is susceptible or resistant to treatment with the compound. The method includes establishing whether the patient is a pre-adult, a transition age patient, or an adult and observing whether the genome of the patient contains at least one copy of a BDNF allele having a genetic alteration. The method further includes correlating the presence of the allele containing the genetic alteration with susceptibility or resistance of the patient to the treatment with the compound, wherein a pre-adult patient containing the genetic alteration is correlated as being susceptible to the treatment; a transition age patient containing the genetic alteration is correlated as being susceptible or resistant to the treatment; and an adult patient containing the genetic alteration is correlated as being resistant to the treatment. | 08-25-2011 |
20120022167 | Trans-Clomiphene for Metabolic Syndrome - The present invention relates to the administration of compositions comprising an antiestrogen, preferably trans-clomiphene, for treating metabolic syndrome in a subject. The invention is also directed to methods for reducing fasting glucose levels in a subject by administering a composition comprising an antiestrogen, preferably trans-clomiphene. | 01-26-2012 |
20120214875 | PHENOXYBENZAMINE ASSAY - The invention provides methods for measuring concentrations of basic or neutral compounds, such as phenoxybenzamine, in biological samples, and methods for treating patients based on the compound concentrations in the biological samples from the patients. | 08-23-2012 |
20120329878 | PHENOTYPING TUMOR-INFILTRATING LEUKOCYTES - The present disclosure relates to an immune signature of tumor infiltrating leukocytes. In particular, the disclosure provides methods and kits for determining the immune signature of tumor infiltrating leukocytes for use in assessing risk of cancer recurrence and long term survival, and for developing a treatment regimen for a cancer patient. | 12-27-2012 |
20130079418 | Phoshorylation of Estrogen Receptor Alpha Serine 282 as a Marker for Endocrine Therapies in Breast Cancer - The present invention provides diagnostic methods and markers based on the phosphorylation state of certain amino acid residues of estrogen receptor α. The invention relates to the phosphorylation of specific estrogen receptor alpha residues as a marker for susceptibility to chemotherapy. The invention specifically discloses the phosphorylation of serine 282 of the ER-alpha, as a diagnostic marker for breast cancer cells which are more responsive to hormone therapy than cells without the said phosphorylation. | 03-28-2013 |
20130150453 | SOLID DAPOXETINE - The present invention relates to solid racemic dapoxetine, solid dapoxetine S(+)enantiomer, processes for their preparation and their use in the pharmaceutically active compound dapoxetine acid addition salt, and pharmaceutical compositions thereof. | 06-13-2013 |
20130253064 | STYRENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS - The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease. | 09-26-2013 |
20140206770 | ANDROGEN RECEPTOR-DEPENDENT GENE EXPRESSION CONTROL - Disclosed is the use of at least one amine oxidase inhibitor for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal and to pharmaceutical compositions for controlling the androgen receptor-dependent gene expression, comprising an effective dose of at least one amine oxidase inhibitor suitable for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal. | 07-24-2014 |
20140221496 | Method of Diagnosis or Prognosis of a Neoplasm Comprising Determining the Level of Expression of a Protein in Stromal Cells Adjacent to the Neoplasm - The invention provides diagnostic and therapeutic methods for neoplastic disease patients with neoplasms of, for example, the breast, skin, kidney, lung, pancreas, rectum and colon, prostate, bladder, epithelial, non-epithelial, lymphomas, sarcomas, melanomas, and the like, wherein the method comprises determining the level of expression o caveolin-1, caveolin-2, vimentin, calponin2, tropomyosin, gelsolin, prolyl 4-hydroxylase alpha, EF-I-delta, or M2-isoform of pyruvate kinase in stromal cells adjacent to the neoplasm. | 08-07-2014 |
20140303256 | PHARMACEUTICAL COMPOSITION COMPRISING FLUOXETINE AS AN ACTIVE INGREDIENT FOR PREVENTING OR TREATING BLOOD-BRAIN DISORDERS - The present invention relates to a pharmaceutical composition for the prevention and treatment of blood-brain barrier disorder comprising fluoxetine as an active ingredient. More particularly, fluoxetine inhibits the expressions of matrix metalloproteinase(MMP)-2, MMP-9, and MMP-12, which are reported to be related to blood-brain barrier (BBB) disruption and inflammatory reaction after spinal cord injury, specifically inhibits the activations of MMP-2 and MMP-9, inhibits the decomposition of ZO-1, the most representative tight junction protein, so as to maintain tight junction between endothelial cells and to protect blood-brain barrier thereby, inhibits the increase of blood-brain barrier permeability, and inhibits the expressions of chemoattractants of blood cells, such as CXCL-1, CXCL-2, CCL-2, CCL-3 and CCL-4 so as to reduce inflow of blood into spinal cord and recover exercise function which has been deteriorated by spinal cord injury. Therefore, fluoxetine can be effectively used for the prevention and treatment of central nervous system disease, blood-brain barrier disorder, or blood-spinal cord barrier disorder. | 10-09-2014 |
20150011643 | TREATMENT OF HEART FAILURE AND ASSOCIATED CONDITIONS BY ADMINISTRATION OF MONOAMINE OXIDASE INHIBITORS - Administration of monoamine oxidase inhibitors is useful in the prevention and treatment of heart failure and incipient heart failure. | 01-08-2015 |
20150065580 | APPLICATION OF FLUOXETINE TO TREATMENT OF DEPIGMENTATION DISEASES - The present invention relates to the field of medicine and particularly relates to the application of fluoxetine to the treatment of depigmentation diseases. Pharmacodynamic tests have demonstrated that fluoxetine has the effects of treating depigmentation diseases especially leukotrichia and vitiligo. | 03-05-2015 |
20150087718 | COMPOSITIONS AND METHODS RELATING TO DENND1A VARIANT 2 AND POLYCYSTIC OVARY SYNDROME - Provided are compositions and methods for use in polycystic ovary syndrome diagnosis (PCOS). The method involves a sample from a subject for a DENND1A Variant 2 mRNA or DENND1 A Variant 2 protein to make or aid in a diagnosis of PCOS. Also provided are methods for selecting an individual as a candidate for therapy for polycystic ovary syndrome by testing a biological sample from an individual for DENND1 A Variant 2 mRNA or DENND1 A Variant 2 protein and designating the individual as a candidate for the PCOS based on determining DENND1 A Variant 2 mRNA or DENND1 A Variant 2 protein in the sample. Also provided are products for use in aiding diagnosis of PCOS which contain reagents for detecting DENND1 A Variant 2 mRNA or DENND1 A Variant 2 protein, and packaging containing printed material describing use and indications for the product. | 03-26-2015 |
20150094377 | HEREDITARY CANCER GENES - The invention generally relates to a molecular classification of disease predisposition and particularly to molecular markers for cancer predisposition and methods of use thereof. | 04-02-2015 |
20150133562 | Atomoxetine Solution - The present invention provides a novel palatable pharmaceutical composition in the form of aqueous solution of atomoxetine. The oral aqueous solution of this invention will significantly reduce the potently bitter taste of atomoxetine, and further avoid swallow issue for young and elderly patients. | 05-14-2015 |
20150148426 | NOVEL MODULATORS OF CORTICAL DOPAMINERGIC- AND NMDA-RECEPTOR-MEDIATED GLUTAMATERGIC NEUROTRANSMISSION - The present invention relates to novel substituted phenoxyethylamine derivatives, useful as modulators of cortical and basal ganglia dopaminergic and N-methyl-D-aspartate (NMDA) receptor-mediated glutamatergic neurotransmission. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention. | 05-28-2015 |
20150344966 | Hereditary Cancer Diagnostics - The disclosure generally relates to a molecular classification of disease predisposition and particularly to molecular markers for cancer predisposition and methods of use thereof. | 12-03-2015 |
20160074343 | ENERGY DRINKS AND OTHER NUTRITIONAL AIDS DERIVED FROM AGAVE-BASED SPIRITS - Compositions containing monoamine oxidase inhibitors prepared by removal of alcohol from agave-derived beverages are disclosed. | 03-17-2016 |
20160089349 | CB2 RECEPTOR LIGANDS FOR THE TREATMENT OF PSYCHIATRIC DISORDERS - The present invention provides cannabinoid type 2 (CB2) receptor inverse agonists for treating or ameliorating psychiatric disorders. The present invention further provides pharmaceutical compositions comprising 4′-O-methylhonokiol for treating Attention Deficit Hyperactivity Disorder (ADHD) and Tourette's syndrome. | 03-31-2016 |
20160250162 | Epinephrine and Benadryl Delivery Method and Apparatus | 09-01-2016 |
514652000 | Alkanol group only between the amino nitrogen and an ether oxygen which is bonded directly to the aryl ring or aryl ring system (i.e., aryloxy alkanol amines) | 18 |
20080242732 | Liver selective drug therapy - A method of pharmaceutical therapy comprising administering at least one pharmaceutical, complementary medicine, or herbal product, orally at a dose sufficient to provide a clinically effective blood level in the portal vein and less than that required to provide a clinically effective blood level in the peripheral circulation to thereby provide a dose-delivery rate having a selective clinical effect in the liver. | 10-02-2008 |
20090012181 | Patch - A Bisoprolol patch, wherein the skin penetration rate of Bisoprolol after 24 hours is 15 to 60% of the maximum skin penetration rate thereof, shows a little difference between the maximum level of the concentration in blood and the minimum level thereof in repeated administration and, therefore, scarcely exhibits side effects. Moreover, it achieves the quick development of the drug effect owing to the stabilization of the concentration in blood within a short time. | 01-08-2009 |
20090247642 | SYNTHESIS AND PREPARATIONS OF METOPROLOL AND ITS SALTS - The invention relates to an improved process for preparing metoprolol and its salts. | 10-01-2009 |
20090253801 | Novel Antiarrhythmic Drug Formulations - The present invention provides a method of achieving a novel Propafenone formulation, which will have reduced number dosings and improved bioavailability. The present invention also applies to the salt and active metabolites of the parent and pro-drug. The novel compositions are designed to release Propafenone after oral intake in a manner, which enables absorption to take place in the gastrointestinal tract so that a relatively fast peak plasma concentration of the active is obtained. The time-specific pharmaceutical formulation, the disintegration of which is triggered by time lapse and the pH of the environment to which it is subjected. The novel compositions are also designed for administration once or twice daily. i.e. a therapeutically effective concentration of Propafenone is maintained for a period of at least 10-20 hours. A composition is designed to release Propafenone in at least the following consecutive steps: i) an initial relatively fast release of Prop afenone, ii) a second rise in release of Propafenone about 1-6 hours after oral intake; and iii) a third rise in release of Propafenone about 4-15 hours after oral intake, depending upon ones metabolism. | 10-08-2009 |
20090264535 | LIQUID DRUG FORMULATION - The invention relates to a liquid drug formulation for beta-blockers, which is suitable in particular for oral application in animals. | 10-22-2009 |
20100227932 | Patch - A Bisoprolol patch, wherein the skin penetration rate of Bisoprolol after 24 hours is 15 to 60% of the maximum skin penetration rate thereof, shows a little difference between the maximum level of the concentration in blood and the minimum level thereof in repeated administration and, therefore, scarcely exhibits side effects. Moreover, it achieves the quick development of the drug effect owing to the stabilization of the concentration in blood within a short time. | 09-09-2010 |
20100273889 | USE OF A BETA BLOCKER FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HEMANGIOMAS - The present invention relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present invention provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas. | 10-28-2010 |
20100305213 | TREATMENT OF HEART DISEASE USING BETA-BLOCKERS - The present invention relates to a method of reversing the electrophysiological cardiac remodeling of animals with heart disease. More specifically, the method includes administering to an animal in need thereof a β-adrenoceptor blocker. | 12-02-2010 |
20120035270 | PAEDIATRIC SOLUTIONS COMPRISING A BETA-BLOCKER - The present invention relates to aqueous non alcoholic solutions comprising a beta-blocker, a non sugar type sweetener and being substantially free of an aromatic preservative agent. The solutions of the present invention are particularly adapted for a paediatric use. | 02-09-2012 |
20120220665 | Inhibiting Neurotransmitter Reuptake - This document relates to compounds as well as methods and materials involved in modulating neurotransmitter reuptake. For example, compounds, methods for synthesizing compounds, and methods for inhibiting neurotransmitter reuptake are provided. | 08-30-2012 |
20130225688 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SOMATOSENSORY DISORDERS - A method of combating a somatosensory disorder in a subject, comprising administering to the subject an effective amount of a composition comprising bupranolol and/or pharmaceutically acceptable derivative(s) thereof. Compositions useful for such administration are described, including salts, esters, solvates, etc. of tert-butyl[3-(2-chloro-5-methylphenoxy)-2-hydroxypropyl]amine, in which such salt, ester, solvate, etc. compound is in enantiomeric excess or homoenantiomeric in the R isomer thereof, or is formulated with racemic mixtures of the R and S stereoisomers of the salts, esters, solvates, etc. of tert-butyl[3-(2-chloro-5-methylphenoxy)-2-hydroxypropyl]amine. Combination therapy compositions of opioid receptor agonists and such compounds are also described. A method is disclosed of referential genotypic screening of candidate subjects in connection with therapeutic intervention using the compositions of the disclosure to combat the somatosensory disorder. | 08-29-2013 |
20140357724 | BETA 2 ADRENOCEPTOR ANTAGONISTS FOR TREATING ORTHOSTATIC HYPOTENSION - Methods of treating orthostatic hypotension are disclosed. The methods include administering to a subject in need thereof an effective amount of a beta 2 (β2) adrenoceptor antagonist, and in particular, the specific β2 adrenoceptor antagonist, 3-(isopropylamino)-1-[(7-methyl-4-indanyl)oxy]butan-2-ol. | 12-04-2014 |
20140371322 | Phenoxybenzamine Transdermal Composition - A phenoxybenzamine transdermal composition for treating neuropathic pain is disclosed. The phenoxybenzamine transdermal composition may include phenoxybenzamine in a concentration of about 5 mg/g to about 120 mg/g, with about 15 mg/g being preferred, in combination with a pharmaceutically suitable permeation enhancer that may be included in amounts of about 20% by weight to about 99.95% by weight, with about 50% by weight being preferred. Permeation enhancer composition within disclosed phenoxybenzamine transdermal composition may improve penetration of phenoxybenzamine in a patient's tissue or skin. The phenoxybenzamine transdermal composition may provide a long duration blockade of sensitized pain receptors of 24 hours or more, resulting in an effective treatment for neuropathic pain with lower concentrations of phenoxybenzamine and requiring fewer applications. | 12-18-2014 |
20150087719 | PAEDIATRIC SOLUTIONS COMPRISING A BETA-BLOCKER - The present invention relates to aqueous non alcoholic solutions comprising a beta-blocker, a non sugar type sweetener and being substantially free of an aromatic preservative agent. The solutions of the present invention are particularly adapted for a paediatric use. | 03-26-2015 |
20160022612 | OXPRENOLOL COMPOSITIONS FOR TREATING CANCER - The present invention relates to compositions of S-enantiomer enriched oxprenolol and their use in treating cancer and treating or preventing, in cancer patients, cachexia, body weight loss, lean body mass loss and adipose tissue loss, and improving quality of life and prolonging survival of cancer patients. | 01-28-2016 |
20160022613 | S-ENANTIOMERICALLY ENRICHED COMPOSITIONS OF BETA BLOCKERS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS - The present invention relates to S-enantiomerically enriched compositions of beta blockers and uses thereof, including uses of the beta blocker compositions for treating amyotrophic lateral sclerosis. The beta blocker compositions can also be used for preventing loss of lean mass, preventing body weight loss in subjects, improving quality of life in subjects, and prolonging survival in amyotrophic lateral sclerosis patients. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof. | 01-28-2016 |
20160095826 | METHODS OF DIAGNOSIS AND TREATMENT - A method for diagnosing a cardiac ischemic event and a kit for detecting biomarkers used in the method. Also provided is a method for treating a PPAR-related disorder by administering a pharmaceutical composition containing one or more long chain fatty acids. | 04-07-2016 |
20160158167 | THERAPEUTIC AGENTS FOR USE IN THE PROPYLAXIS AND/OR TREATMENT OF HYPERKINETIC MOVEMENT DISORDERS - (RS)-[2-(3,4-dimethoxyphenyl)ethyl][2-hydroxy-3-(3-methylphenoxy)propyllamine having the formula (IA), or a pharmaceutically acceptable salt thereof for the formulation of a pharmaceutical composition is useful for the prophylaxis and/or the treatment of hyperkinetic movement disorders associated with Huntington's disease, Wilson's disease, Tourette syndrome, restless leg syndrome, and tardive dyskinesia. | 06-09-2016 |